Aldosterone-induced inflammation in the rat heart: Role of oxidative stress

American Journal of Pathology

Volumn 161, Issue 5, 2002, Pages 1773-1781

  Sun, Yao ^a   Zhang, Jiakun ^a   Lu, Li ^a   Chen, Sue S ^a   Quinn, Mark T ^b   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACETYLCYSTEINE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANTIOXIDANT; CATECHOLAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROHORMONE; PYRROLIDINE DITHIOCARBAMATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE;

ANIMAL MODEL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; FIBROSIS; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MALE; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE;

EID: 0036841807     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64454-9     Document Type: Article

References (71)

1. Weglicki WB, Kramer JH, Mak IT: The role of antioxidant drugs in oxidative injury of cardiovascular tissue Heart Fail Rev 1999, 4:183-192
2. Ball AM, Sole MJ: Oxidative stress and the pathogenesis of heart failure. Cardiol Clin 1998, 16:665-675
3. Keith ME, Jeejeebhoy KN, Langer A, Kurian R, Barr A, O'Kelly B, Sole MJ: A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 2001, 73:219-224
4. Sole MJ, Jeejeebhoy KN: Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000, 3:417-424
5. Singal PK, Khaper N, Farahmand F, Bello-Klein A: Oxidative stress in congestive heart failure. Curr Cardiol Rep 2000, 2:206-211
6. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, Kajstura J, Leri A, Anversa P: Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001, 89:279-286
7. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A: Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999, 85:357-363
8. Nath R, Kumar D, Li T, Singal PK: Metallothioneins, oxidative stress and the cardiovascular system. Toxicology 2000, 155:17-26
9. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996, 97:1916-1923
10. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, Cohen RA: Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998, 82:810-818
11. Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW: Oxidative stress in the Dahl hypertensive rat. Hypertension 1997, 30:1628-1633
12. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997, 95:588-593
13. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA: Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium. Hypertension 1999, 33:1353-1358
14. Haugen EN, Croatt AJ, Nath KA: Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 2000, 58:144-152
15. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, Nakamura K, Ichikawa K, Utsumi H, Takeshita A: Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001, 104:134-136
16. McMurray J, McLay J, Chopra M, Bridges A, Belch JJ: Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990, 65:1261-1262
17. Belch JJ, Bridges AB, Scott N, Chopra M: Oxygen free radicals and congestive heart failure Br Heart J 1991, 65:245-248
18. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E: Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996, 131:146-152
19. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:1352-1356
20. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ: Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med 1993, 14:643-647
21. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC: NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats Hypertension 2000, 35:193-201
22. 2 receptor-mediated P-selectin upregulation. Circulation 2000, 102:2118-2123
23. Mervaala EM, Müller DN, Park JK, Schmidt F, Löhn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33:389-395
24. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992, 19:464-474
25. Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101:1722-1728
26. Gryglewski RJ, Palmer RM, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456
27. 2α. Hypertension 1999, 33:424-428
28. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000, 20:2175-2183
29. Singal PK, Beamish RE, Dhalla NS: Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983, 161:391-401
30. Taddei S, Virdis A, Mattel P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929-933
31. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC: Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002, 2:3
32. Hayashi K, Takahata H, Kitagawa N, Kitange G, Kaminogo M, Shibata S: N-acetylcysteine inhibited nuclear factor-κB expression and the intimal hyperplasia in rat carotid arterial injury. Neurol Res 2001, 23:731-738
33. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990, 67:1355-1364
34. Burritt JB, Quinn MT, Jutila MA, Bond CW, Jesaitis AJ: Topological mapping of neutrophil cytochrome b epitopes with phage-display libraries. J Biol Chem 1995, 270:16974-16980
35. Sun Y, Ratajska A, Weber KT: Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995, 126:95-101
36. Hilgers KF, Hartner A, Porst M, Veelken R, Mann JF: Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: Relation to kidney inflammation. Circulation 2001, 104:1436-1440
37. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996, 271: C1424-C1437
38. May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 1998, 19:80-88
39. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575
40. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, Cohen RA: An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 1995, 268:H2274-H2280
41. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci USA 1997, 94:14483-14488
42. Mohazzab KM, Kaminski PM, Wolin MS: NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994, 266:H2568-H2572
43. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT: Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996, 271:H1626-H1634
44. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001, 37: 781-786
45. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND: Lead-induced hypertension: Interplay of nitric oxide and reactive oxygen species. Hypertension 1997, 30:1487-1492
46. Shen K, DeLano FA, Zweifach BW, Schmid-Schonbein GW: Circulating leukocyte counts, activation, and degranulation in Dahl hypertensive rats. Circ Res 1995, 76:276-283
47. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schonbein GW: A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999, 6:179-187
48. Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138-147
49. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901
50. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis J Clin Invest 1994, 93:2578-2583
51. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269: E657-E662
52. Delva P, Pastori C, Degan M, Montesi G, Brazzarola P, Lechi A: Intralymphocyte free magnesium in patients with primary aldosteronism: Aldosterone and lymphocyte magnesium homeostasis. Hypertension 2000, 35:113-117
53. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM: Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: Effects of substance P-receptor inhibition. Mol Ceil Biochem 1994, 130:103-109
54. Mann DL: Tumor necrosis factor and viral myocarditis: The fine line between innate and inappropriate immune responses in the heart. Circulation 2001, 103:626-629
55. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJS: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96:526-534
56. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727
57. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964-971
58. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206
59. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001, 103:2055-2059
60. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729
61. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL: Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993, 92:2303-2312
62. Bozkurt B, Kribbs SB, Clubb Jr FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391
63. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C: The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000, 35:537-544
64. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJS: Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999, 83:612-615
65. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel J-B: Inflammatory cells and myocardial fibrosis: Spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996, 32:1096-1107
66. Nicoletti A, Mandet C, Challah M, Bariety J, Michel JB: Mediators of perivascular inflammation in the left ventricle of renovascular hypertensive rats Cardiovasc Res 1996, 31:585-595
67. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697
68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes W: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341: 709-717
69. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC: Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999, 85:29-37
70. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597
71. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circ 2000, 102:2700-2706